已收盤 11-06 16:00:00 美东时间
+0.200
+2.45%
今日重点评级关注:Canaccord Genuity:维持Viking Therapeutics"买入"评级,目标价从106美元升至118美元;Canaccord Genuity:维持Aclaris Therapeutics"买入"评级,目标价从10美元升至13美元
11-02 18:53
Canaccord Genuity analyst Susan Anderson maintains Enhanced Group (NYSE:ENHA) with a Buy and raises the price target from $5 to $17.
10-31 08:41
Enhanced Group Inc. (NYSE: ENHA) (“Enhanced” or the “Company”) today announced that its previously announced 1-for-10 reverse stock split of its Class A and Class B common stock (the “Reverse Stock Split”) has gone effective. Enhanced’s Class A common stock will begin trading on a split-adjusted bas...
10-29 22:41
Enhanced Group(ENHA) announced that its board of directors, backed by written consent from the majority voting shareholder has approved a 1-for-10 reverse stock split of its Class A and Class B common...
09-29 12:54
今日重点评级关注:Leerink Partners:维持塞德斯医疗"跑赢大市"评级,目标价从70美元升至88美元;HC Wainwright & Co.:维持TriSalus Life Sciences"买入"评级,目标价从11美元升至12美元
09-24 16:10
Cantor Fitzgerald analyst Gabie Ingoglia initiates coverage on Enhanced Group (NYSE:ENHA) with a Overweight rating and announces Price Target of $4.
09-23 18:48
Enhanced Group Inc. press release (ENHA): Q2 GAAP EPS of -$0.27. More on Enhanced Group Inc. Historical earnings data for Enhanced Group Inc. Financial information for Enhanced Group Inc.
08-27 04:29
今日重点评级关注:Canaccord Genuity:维持Cardiol Therapeutics"买入"评级,目标价从8美元升至10美元;B. Riley证券:维持Macrogenics"买入"评级,目标价从9美元升至11美元
08-18 11:39
Canaccord Genuity analyst Susan Anderson maintains Enhanced Group (NYSE:ENHA) with a Buy and lowers the price target from $6 to $5.
08-17 20:23
Enhanced Group (NYSE:ENHA) reported quarterly losses of $(0.53) per share. The company reported $17.700 million in sales this quarter.
08-14 04:35